急性重症溃疡性结肠炎的管理:临床最新进展
MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE.
作者信息
Sobrado Carlos Walter, Sobrado Lucas Faraco
机构信息
Discipline of Coloproctology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, SP, Brazil.
出版信息
Arq Bras Cir Dig. 2016 Jul-Sep;29(3):201-205. doi: 10.1590/0102-6720201600030017.
INTRODUCTION
Acute severe colitis is a potentially lethal medical emergency and, even today, its treatment remains a challenge for clinicians and surgeons. Intravenous corticoid therapy, which was introduced into the therapeutic arsenal in the 1950s, continues to be the first-line treatment and, for patients who are refractory to this, the rescue therapy may consist of clinical measures or emergency colectomy.
OBJECTIVE
To evaluate the indications for and results from drug rescue therapy (cyclosporine, infliximab and tacrolimus), and to suggest a practical guide for clinical approaches.
METHODS
The literature was reviewed using the Medline/PubMed, Cochrane library and SciELO databases, and additional information from institutional websites of interest, by cross-correlating the following keywords: acute severe colitis, fulminating colitis and treatment.
RESULTS
Treatments for acute severe colitis have avoided colectomy in 60-70% of the cases, provided that they have been started early on, with multidisciplinary follow-up. Despite the adverse effects of intravenous cyclosporine, this drug has been indicated in cases of greater severity with an imminent risk of colectomy, because of its fast action, short half-life and absence of increased risk of surgical complications. Therapy using infliximab has been reserved for less severe cases and those in which immunosuppressants are being or have been used (AZA/6-MP). Indication of biological agents has recently been favored because of their ease of therapeutic use, their good short and medium-term results, the possibility of maintenance therapy and also their action as a "bridge" for immunosuppressant action (AZA/6-MP). Colectomy has been reserved for cases in which there is still no response five to seven days after rescue therapy and in cases of complications (toxic megacolon, profuse hemorrhage and perforation).
CONCLUSION
Patients with a good response to rescue therapy who do not undergo emergency operations should be considered for maintenance therapy using azathioprine. A surgical procedure is indicated for selected cases.
引言
急性重症结肠炎是一种潜在致命的医疗急症,即便在当今,其治疗对临床医生和外科医生而言仍是一项挑战。20世纪50年代被纳入治疗手段的静脉用皮质类固醇疗法仍是一线治疗方法,对于对此疗法难治的患者,挽救疗法可能包括临床措施或急诊结肠切除术。
目的
评估药物挽救疗法(环孢素、英夫利昔单抗和他克莫司)的适应证及疗效,并提出临床治疗的实用指南。
方法
通过交叉关联以下关键词,利用Medline/PubMed、Cochrane图书馆和SciELO数据库对文献进行综述,并从相关机构网站获取更多信息:急性重症结肠炎、暴发性结肠炎和治疗。
结果
急性重症结肠炎的治疗在60%至70%的病例中避免了结肠切除术,前提是早期开始治疗并进行多学科随访。尽管静脉用环孢素有不良反应,但因其作用迅速、半衰期短且手术并发症风险未增加,已被用于病情更严重、有即将进行结肠切除术风险的病例。英夫利昔单抗疗法适用于病情较轻以及正在使用或已使用免疫抑制剂(硫唑嘌呤/6-巯基嘌呤)的病例。由于生物制剂使用方便、近期和中期疗效良好、可进行维持治疗以及可作为免疫抑制剂作用的“桥梁”(硫唑嘌呤/6-巯基嘌呤),近年来其应用更受青睐。结肠切除术适用于挽救治疗五至七天后仍无反应以及出现并发症(中毒性巨结肠、大量出血和穿孔)的病例。
结论
对挽救疗法反应良好且未接受急诊手术的患者应考虑使用硫唑嘌呤进行维持治疗。部分病例需进行手术治疗。
相似文献
Arq Bras Cir Dig. 2016
Cochrane Database Syst Rev. 2005-1-25
Gut. 2010-10-28
Dig Liver Dis. 2008-10
Nat Clin Pract Gastroenterol Hepatol. 2007-2
引用本文的文献
Pharmaceuticals (Basel). 2025-2-23
J Anus Rectum Colon. 2024-7-30
Evid Based Complement Alternat Med. 2022-3-7
Gastroenterol Res Pract. 2019-2-28
Inflamm Bowel Dis. 2019-1-1
本文引用的文献
J Crohns Colitis. 2010-2-19
Inflamm Bowel Dis. 2010-9
Am J Gastroenterol. 2008-4
Aliment Pharmacol Ther. 2007-9-1
Clin Gastroenterol Hepatol. 2007-1